REVIEW COMBINED LIPID-LOWERING THERAPY IN EUROPEAN SOCIETY OF CARDIOLOGY AND EUROPEAN ATHEROSCLEROSIS SOCIETY (ESC/EAS) 2019 GUIDELINES: PLACE OF EZETEMIBE

Cover Page

Cite item

Full Text

Abstract

The article provides information about the place of ezetimibe in the latest edition of the joint recommendations of the European Society of Cardiology and the European Atherosclerosis Society of 2019, dedicated to the correction of lipid metabolism disorders in order to prevent and treat clinical complications of atherosclerosis. The material of the recommendations is discussed from the point of current conception of the effectiveness and safety of the inhibitor of intestinal absorption of cholesterol - ezetimibe, which is widely used in combined lipid-lowering therapy. The features of the use of ezetimibe in combination with statins to achieve target lipid levels and reduce the frequency of side effects of first-line drugs are detailed. New approaches to stratification of cardiovascular risk in European and Russian recommendations for the diagnosis and treatment of atherogenic dyslipidemia are compared. The possibilities of combined lipid-lowering therapy to achieve new target levels of low density lipoprotein cholesterol in patients with high and very high cardiovascular risk are discussed.

About the authors

Victor S. Gurevich

Saint Petersburg State University; Mechnikov North-Western State Medical University; Sokolov Clinical Hospital №122

Email: vktrgurevich@gmail.com
д-р мед. наук, проф.

References

  1. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019; 00:1-78.
  2. Ежов М.В., Сергиенко И.В., Аронов Д.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. Атеросклероз и дислипидемии.2017;3:3-22. @@Ezhov M.V., Sergienko I.V., Aronov D.M. et al. Diagnostika i korrektsiia narushenii lipidnogo obme-na s tsel'iu profilaktiki i lecheniia ateroskleroza. Rossiiskie rekomendatsii, VI peresmotr. Ateroskle-roz i dislipidemii. 2017; 3: 3-22. (in Russian).
  3. Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019; 00: 1-71.
  4. Сергиенко И.В., Шестакова М.В., Бойцов С.А. и др. Экстремальная категория риска в системе стратификации сердечно-сосудистых осложнений. Консенсус совета экспертов. Фарматека. 2019; 26: 138-43. @@Sergienko I.V., Shestakova M.V., Boitsov S.A. et al. Ekstremal'naia kategoriia riska v sisteme stra-tifikatsii serdechno-sosudistykh oslozhnenii. Konsensus soveta ekspertov. Farmateka. 2019; 26: 138-43 (in Russian).
  5. Гуревич В.С. Место эзетимиба в оптимальной гиполипидемической терапии согласованные позиции и дискуссионные вопросы. Рус. мед. журн. Мед. обозрение. 2019; 6: 11-6. @@Gurevich V.S. Mesto ezetimiba v optimal'noi gipolipidemicheskoi terapii soglasovannye pozitsii i diskussionnye voprosy. Rus. med. zhurn. Med. obozrenie. 2019; 6: 11-6 (in Russian).
  6. Cannon CP, Giugliano RP, Blazing MA et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156: 826-32.
  7. Giugliano RP, Cannon CP, Blazing MA et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2018; 137: 1571-82.
  8. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377 (9784): 2181-92.
  9. Catapano A, Graham I, deBacker GD et al. 2016 ESC/EAS Guidelines for the Management of Dys-lipideamias. The Task Force for the management of Dyslipideamias. Eur Heart J 2016; 37 (39): 2999-3058.
  10. Кобалава Ж.Д., Гуревич В.С., Галявич А.С. и др. Возможности клинического применения препарата эзетимиба Отрио (АО «АКРИХИН», Россия) у пациентов высокого и очень высокого сердечно-сосудистого риска, не достигших целевых значений показателей липидного обмена. Заключение совета экспертов. Кардиология. 2019; s5: 47-57.
  11. Толкачева В.В., Малая И.П., Багманова Н.Х., Кобалава Ж.Д. Изучение биоэквивалентности препаратов эзетимиба у здоровых добровольцев после однократного приема натощак. Consilium Medicum. 2019; 21 (1): 87-91. doi: 10.26442/20751753.2019.1.190205

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies